Jeffrey Maxwell Holzbeierlein MDDirector of the Division of Urologic Oncology, University of Kansas Hospital, Director of Clinical Research for the Urology Department at Kansas University, Kansas City, KS.
Dr. Jeffrey Maxwell Holzbeierlein, is a native of Edmond, Oklahoma. He attended Vanderbilt University where he played on the men’s tennis team for his 4 years and was the captain of the team during his senior year. He then completed his medical degree at the University of Oklahoma before returning to Vanderbilt to complete his residency in Urology. After completion of his residency, Dr. Holzbeierlein spent 2 years doing his fellowship at Memorial Sloan Kettering Cancer Center in Urologic Oncology before joining the faculty at the University of Kansas Medical Center in Kansas City, Kansas in 2002.
Dr. Holzbeierlein’s research interests focus on the androgen receptor and Heat Shock Protein 90. He continues to have an active basic science laboratory whose work has been supported by a Department of Defense New Investigator award on which he was the Principal Investigators and 2 R01 grants on which he is a co-investigator. His clinical research has focused on bladder cancer including identification of clinical factors that predict response to chemotherapy and immunonutrition for patients undergoing cystectomy. He is currently, the Director of the Division of Urologic Oncology at the University of Kansas Hospital and the Director of Clinical Research for the Urology Department at KU. He has numerous peer reviewed publications both in basic science and clinical research.
Recent Contributions to PracticeUpdate:
- Outcomes of Subsequent Non–Muscle Invasive Bladder Cancer Treated With Intravesical BCG After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
- Reducing Overutilization of Preoperative Medical Referrals Among Patients Undergoing Radical Cystectomy Using an Evidence-Based Algorithm
- Concomitant Carcinoma and Neoadjuvant Chemotherapy for Urothelial Cell Carcinoma